SkyAI, Inc.
Close on Oct 19, 2026
- Market cap
- $201.14M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
SkyAI has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements SkyAI filed with the SEC
to Commence $3.00 Per Share/Warrant Tender Offer and File Offer Materials with the SEC After Market Close on October 15, 2026
Other events · EX-99.1 to Form 8-K
Announces Intention to Commence Cash Tender Offer to Purchase Common Stock and Pre-funded Warrants at $3.00 Per Share/Pre-funded Warrant
Other events · EX-99.1 to Form 8-K
Technology Becomes SkyAI, Inc. with New Ticker Symbol “SKYA”; Establishing Category-defining Agentic Finance Platform Serving
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Technology Strengthens Market Confidence with Advisor Lock-Up Agreement
Material agreement · Other events · EX-99.1 to Form 8-K
AND RESTATED AUDIT COMMITTEE CHARTER
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
AND RESTATED COMPENSATION COMMITTEE CHARTER
Charter or bylaw amendment · Other events · EX-99.2 to Form 8-K
& CORPORATE GOVERNANCE COMMITTEE CHARTER
Charter or bylaw amendment · Other events · EX-99.3 to Form 8-K
Technology Announces $100 Million Stock Repurchase Program
Other events · EX-99.1 to Form 8-K
Prepared at the Direction of Counsel
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Prepared at the Direction of Counsel
Material agreement · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Shareholder vote results · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Material agreement · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Shareholder vote results · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Technology Begins Shipments Across Three Customer Orders Under Previously Announced Purchase Agreements
Regulation FD disclosure · EX-99.1 to Form 8-K
Technology Regains Compliance with Nasdaq Minimum Bid Price Listing Rule
Regulation FD disclosure · EX-99.1 to Form 8-K
Technology Receives ~$100K Initial Purchase Order from Hungarian Vaccine Provider for SecureGard™ Syringes
Regulation FD disclosure · EX-99.1 to Form 8-K
Technology Secures $400K Initial Purchase Order from U.S. Leader in IV Flushing Solutions as Part of $50 Million SoloGard Supply Agreement
Regulation FD disclosure · EX-99.1 to Form 8-K
Sharps Technology Announces Reverse Stock Split
Regulation FD disclosure · EX-99.1 to Form 8-K
Technology, Inc. Reminds Shareholders to Vote Before Important Shareholder Meeting on March 28, 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
Technology’s CEO Issues Shareholder Letter Highlighting Hungary Manufacturing Facility Expansion Plans to Increase SecureGard and
Regulation FD disclosure · EX-99.1 to Form 8-K
Technology Signs Sales Agreements to Support Major European Healthcare Network and Sells Out Its Inventory for SecureGard
Regulation FD disclosure · EX-99.1 to Form 8-K
TECHNOLOGY, INC. ANNOUNCES STOCKHOLDERS’ APPROVAL OF REVERSE STOCK SPLIT RATIO AND EFFECTIVE DATE
Regulation FD disclosure · EX-99.1 to Form 8-K
Technology, Inc. Reminds Shareholders to Vote Before Important Shareholder Meeting on October 7, 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
Technology, Inc. Announces $3.5 Million Bridge Financing
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Technology Announces Continued Listing on Nasdaq Pending Results of an Upcoming Special Shareholders’ Meeting
Regulation FD disclosure · EX-99.1 to Form 8-K
Technology Enters Into a Five-Year Sales Agreement with Strategic U.S. Medical Products Company Creating +$5O Million in New Revenue
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Technology CEO Urges Shareholders to Vote in Support of the Three Proposals by the July 12 Voting Deadline
Regulation FD disclosure · EX-99.1 to Form 8-K
Technology Urges Shareholders to Approve the Proposals in connection with the Special Meeting on July 15, 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
Technology Receives $30 Million Purchase Order for Prefillable Copolymer Syringes to be Manufactured at SC Facility
Regulation FD disclosure · EX-99.1 to Form 8-K
Technology Secures SC Asset Purchase Exclusivity with $1 Million Escrow Deposit
Regulation FD disclosure · EX-99.1 to Form 8-K
Technology’s SC Asset Purchase and $200 Million Syringe Sales Agreement Paves the Way to Begin Producing Prefillable Specialty
Regulation FD disclosure · EX-99.1 to Form 8-K
Technology Positioned to Address Supply Chain Disruptions Resulting from Recent FDA Recalls, Warnings, and Tariffs on Chinese Manufactured
Regulation FD disclosure · EX-99.1 to Form 8-K
Technology and Roncadelle Operations Sign Worldwide Sales and Distribution Agreement for their Innovative Portfolio of Safe Technology
Regulation FD disclosure · EX-99.1 to Form 8-K
Technology Signs LOI with Roncadelle Operations Intended to Open Worldwide Sales and Distribution Opportunities for Safe Drug Delivery
Regulation FD disclosure · EX-99.1 to Form 8-K
Technology Announces $5.6 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Technology Announces Closing of $5.6 Million Registered Direct and Private Placement
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Technology Issues Letter to Shareholders Covering the Announced Asset Purchase Agreement to Acquire InjectEZ Prefillable Syringe Manufacturing
Regulation FD disclosure · EX-99.1 to Form 8-K
Technology Signs Asset Purchase Agreement to Acquire InjectEZ Specialty Copolymer Syringe Manufacturing Facility and
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Technology Announces Pricing of $3.8 Million Private Placement Priced at the Market
Material agreement · Unregistered share sale · Executive or director change · Other events · EX-99.1 to Form 8-K
Technology Announces Closing of $3.8 Million Private Placement Priced At-the-Market
Material agreement · Unregistered share sale · Executive or director change · Other events · EX-99.2 to Form 8-K
Technology Inc. to Introduce New Specialized Prefillable Syringe Systems in 2023
Regulation FD disclosure · EX-99.1 to Form 8-K
Sharps Technology Begins Manufacturing at its Hungary
Regulation FD disclosure · EX-99.1 to Form 8-K